| INTRODUC TI ON
Allogeneic antibodies targeting human leucocyte antigens (HLA) play a central role in the development of antibody-mediated allograft rejection. [1] [2] [3] [4] [5] [6] Mounting evidence suggests that autoreactive antibodies also contribute to rejection and can have an adverse impact on graft outcome in kidney, heart, and lung transplant patients. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Autoantibodies against angiotensin II type 1 receptors (AT1R), vimentin, collagen V, tubulin, and perlecan/LG3 (anti-LG3) have been associated with accelerated allograft rejection in animal models of kidney, heart, and lung transplantation and in transplant patients. 8, 9, 15, 19, 20 In addition, anti-
LG3 antibodies also aggravate ischemia-reperfusion injury (IRI) in renal transplant patients and in murine models through complement activation leading to microvascular rarefaction, fibrosis, and long-term renal allograft dysfunction. [21] [22] [23] Classically, the appearance of autoantibodies was thought to follow episodes of acute rejection leading to the release of danger-associated molecular patterns (DAMPs) that in turn favor autoantibody production. However, in previous studies, anti-AT1R and anti-LG3
autoantibodies have been detected prior to transplantation in patients awaiting a first transplant. 8, 24, 25 These patients had neither allosensitizing conditions nor classic autoimmune diseases.
In the present study, we sought to understand the mechanisms responsible for anti-LG3 production prior to transplantation. We investigated the crosstalk between T cell and B cell responses in controlling anti-LG3 formation.
| MATERIAL AND ME THODS

| Reagents
The mouse perlecan fragment LG3 (aa 3514-3707 with N-terminal His 8 G tag) or a secreted form of red fluorescent protein (RFP1) (with Cterminal His 8 G tag) were cloned into the pTT5™ plasmid. 26, 27 For protein production, 293-6E cells were transfected at 1.8x10 6 cells/ml with pTT5/cDNA constructs. Cultures were harvested at 5 days posttransfection and purified by IMAC on Fractogel®-Cobalt. 28 For some experiments, N-terminal His8G tag was removed from the LG3 construct.
Purified mouse serum albumin (MSA) protein was obtained from Alpha Diagnostic International (San Antonio, TX). Endotoxin levels were measured by Limulus Amebocyte Lysate test using Endosafe-PTS spectrophotometer (Charles River Laboratories, Wilmington, MA) for LG3 (with or without His8G tag) and RFP1 and by clot method for MSA. The levels of endotoxin were respectively equal to 0.016 EU/mg, 0.021 EU/mg, and 1.2 EU/mg.
| Mice
Wild type (WT) female C57BL/6 mice between 5-7 weeks of age were obtained from Charles River (St-Constant, QC, Canada). CD4-deficient mice (B6.129S2-Cd4 tm1Mak ) were purchased from the Jackson Laboratory (Bar Harbor, ME). All animal experiments mice were approved by the Comité Institutionnel de Protection des Animaux (CIPA) of the CRCHUM. Mice were anesthetized using isoflurane (2%) by inhalation and sacrificed by cardiac puncture. For the recovery of peritoneal cavity cells, mice were sacrificed by the dislocation of the cervical vertebrae to prevent blood contamination of peritoneal cavity. 
| Immunization and depletion of CD4
| ELISA
| Cell isolation
Cells were isolated from the spleen, bone marrow, or peritoneal cavity as described. 29, 30 B1 cells and B2 cells were purified from the peritoneal cavity cells. In brief, total B cells were first purified using Easysep . The efficiency of cell enrichment was evaluated by cytometry using antimouse CD19-PE-Cy7 (BD Biosciences) and antimouse CD23-PE. Purity of B1 cell and B2 cell suspension was respectively about 85%-91% and >98%.
| Stimulation of memory B cells
Splenocytes, bone marrow cells, and peritoneal cells were cultured in RPMI-1640 medium supplemented with L-glutamine, 10%
fetal bovine serum (FBS), 100 units/ml of penicillin, and 100 μg/ml of streptomycin (all from Invitrogen Canada Inc, Burlington, ON, Canada), at 37°C in a humidified atmosphere containing 5% CO 2 .
Murine cells were seeded at 4 × 10 6 cells/ml (splenocytes and bone marrow cells) or 2 × 10 6 cells/ml (peritoneal cavity cells) and memory B cells were stimulated with R-848 (1 μg/ml) (Enzo Life Sciences, Farmingdale, NY) in combination with recombinant murine IL-2 (10 ng/ml) (PeproTech, Dollar-des-Ormeaux, QC, Canada) for 3 days. 
| ELISpot assays
| Flow cytometry analysis
| Human study
We performed a retrospective cohort study among the first 31 Anti-LG3 titers remained significantly increased in immunized mice until 13 weeks after the last injection ( Figure 1E ).
Mice express 4 IgG subclasses: IgG1, IgG2a, IgG2b, and IgG3.
IgG2a, IgG2b, and IgG3 subclasses activate complement whereas IgG1 is not complement fixing. 31 Knowing that rejection-accelerating anti-LG3 antibodies are of complement fixing isotypes both in humans and in mice, LG3 production. WT mice were immunized with mouse serum albumin (MSA), an endogenous protein ( Figure 2C ), or red fluorescent protein (RFP1) (Figure 2D ), the latter being produced through similar cloning and purification methods as LG3. Our results showed that neither MSA nor RFP1-immunization induced anti-LG3 production demonstrating the specificity of the anti-LG3 response.
| Memory B cells specific for LG3 are present in nonimmunized WT mice
We observed that most mice immunized with LG3 showed concomitant (10/17) increases in anti-LG3 IgM and IgG antibodies, suggesting a memory response ( Figure 3A) . To assess the memory response to LG3, we used ELISpot assays to evaluate the presence of memory B cells specific to LG3 in the spleen, bone marrow, and peritoneal cavity (PC) of nonimmunized WT mice ( Figure 3B ). MSA was used as negative control. We did not observe significant MSAspecific antibody-secreting cells (ASC) in the spleen, bone marrow, and PC of WT mice. In contrast, LG3-specific IgM-secreting ASC (IgM-ASC) were detected in all compartments (spleen: 120 ± 18; bone marrow: 42 ± 2; PC: 108 ± 24 per 2 × 10 4 cells) ( Figure 3C ).
LG3-specific IgG-ASC were also identified in all three compartments (spleen: 54 ± 9; bone marrow: 38 ± 6; PC: 313 ± 85 per 5 × 10 5 cells), but with a six-to eight-fold higher magnitude in the PC ( Figure 3D ). Collectively, these data demonstrate the presence 2.7% ± 0.2% of total IgM-ASC;
LG3-specific IgG-ASC: 17.3% ± 1.2%
of total IgG-ASC [ Figure 4C] ). In contrast, we did not observe significant LG3-specific ASC in B2 cell population ( Figure 4D ). The quantity of IgM and IgG-ASC reactive to LG3 was respectively about 10-and 22-fold lower in B2 cell populations compared to B1 cells ( Figure 4E,F ). These data demonstrate that B1 cells are the main subset of B cells in the PC with memory specific to LG3.
| CD4 + T cells are central to the production of anti-LG3 antibodies
To evaluate the impact of LG3 on CD4 + T cell function, we studied the effect of LG3-immunization on the naïve, effector, and mem- Figure 5D ). Taken together, these results show that LG3 modulates CD4 + T cell phenotype and that CD4 + T cells are necessary for anti-LG3 production.
| T cell help is not required for B cell memory to LG3
To evaluate the importance of CD4+ T cells in B cell memory to LG3,
we assessed the presence of memory B cells in nonimmunized CD4 
| Immunosuppressive regimens targeting T cell function in renal transplant patients reduce anti-LG3 levels
Having shown that, although B cell memory to LG3 is present in nonimmunized mice, the production of anti-LG3 antibodies is T cell dependent, we sought to evaluate the importance of CD4 + T cells for maintaining anti-LG3 production once it is established.
WT mice were immunized with LG3 as previously described. Two Patient characteristics are found in Table 1 . Anti-LG3 levels were significantly reduced at 1 month posttransplantation compared to pretransplant levels ( Figure 7D ). No variable included in Table 1 was associated with the change in anti-LG3 values posttransplant.
Collectively, these results identify T cell help as a target of intervention for dampening humoral immunity against LG3.
| D ISCUSS I ON
In the present work, we show that exposure to the perlecan fragment LG3, even in the absence of adjuvant, leads to the production LG3 is likely because of the presence of memory B cells, even prior to immunization, in the spleen, bone marrow but most strikingly in the peritoneal cavity of normal mice. We also found that B1 subsets within the peritoneal cavity are the main source of LG3-specific memory B cells. Mouse B1 cells are the predominant constituents of peritoneal B cells and are also found in the pleural cavity, the spleen, and the bone marrow. [32] [33] [34] [35] In contrast to B2 cells, B1 cell development occurs primarily during fetal and perinatal life. B1 cells are effectors of the innate immune system and the main producers of polyreactive antibodies that bind to both microbial antigens and self-antigens, including neo-self epitopes expressed by apoptotic cells such as annexin IV and phosphorylcholine. [36] [37] [38] It has been suggested that natural autoantibodies produced by B1 cells favor the clearance of senescent and apoptotic cells and therefore have protective effector functions. 34, 39 We previously showed that LG3 is produced by apoptotic endothelial cells downstream of caspase-3 activation and released through the production of exosome-like apoptotic membrane vesicles. [40] [41] [42] The presence of a predominant B1
cell memory-response to LG3 in naïve mice suggests that memory to
LG3 is likely a normal and innate response to components of membrane vesicles released by apoptotic cells. Interactions between Several studies show an association between polyreactive natural antibodies, kidney allograft injury, and reduced long-term graft outcome in human. 10, 43, 44 Memory B cells producing natural antibodies with reactivity to multiple HLA alleles, DNA, and self-antigenic structure were found in the blood of patients with kidney graft rejection. 45 As we reported, a high frequency of memory B1 cells specific to LG3 is found in the peritoneal cavity of naïve mice. We do not exclude the possibility that antibodies with reactivity to LG3 also react to a broad range of other antigens. Further studies are needed to evaluate the potential role of polyreactivity in the response to
LG3.
Recent work by our group and others showed an association between the presence of autoantibodies reactive with components of apoptotic cells prior to kidney transplantation and reduced allograft function and survival. 8, 10, 46 In transplant patients, these autoanti- LG3 although we cannot exclude that other factors such as mycophenolate mofetil and corticosteroids also played a role in our observations. Our results point to the possibility that immunosuppressive regimens targeting T cell function could be used prior to transplantation in patients with high anti-LG3 levels as a means of decreasing anti-LG3 levels and potentially preventing the increased risk of delayed graft function, acute rejection, and reduced long-term survival associated with high anti-LG3 levels. 8, 21 In summary, our study provides novel insights into pathways responsible for the production of anti-LG3 autoantibodies. We show that humoral memory specific to perlecan/LG3 is present within the normal repertoire of WT mice and depends in large part on peritoneal B1 cells. Production of anti-LG3 antibodies is not present in naïve normal mice and develops after immunization through CD4 + T cell-dependent pathways. CNI-based immunosuppression is identified as a means of reducing anti-LG3 levels in renal transplant patients, which also concurs to an important role for T cells in controlling anti-LG3 production. Lapointe for helpful scientific discussions. We also wish to thank the personnel of the Animal facility and Flow-cytometry platforms. 
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